EDUCATION

Undergraduate Degree

  • Brown University , 1990 , Providence , RI

Graduate Degree

  • Yale University , 1997 , New Haven , CT

Medical School

  • Yale University School of Medicine , 1998 , New Haven , CT

Internship

  • Boston Children's Hospital , 1999 , Boston , MA

Residency

Pediatics
  • Boston Combined Residency Program (BCRP) , 2002 , Boston , MA

Fellowship

  • Boston Children's Hospital , 2003 , Boston , MA

PROFESSIONAL HISTORY

Dr. Ullrich serves as an expert for the Department of Neurology for Boston Children's Hospital Precision Medicine Service. For more information about the Precision Medicine Service please visit bostonchildrens.org/precisionmed.

CERTIFICATIONS

  • American Board of Psychiatry and Neurology, Child and Adolescent Neurology

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Outcomes after first relapse of childhood intracranial ependymoma. Pediatr Blood Cancer. 2021 Feb 09; e28930. View abstract
  2. The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research. Orphanet J Rare Dis. 2021 02 01; 16(1):61. View abstract
  3. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. Nat Med. 2021 01; 27(1):165-173. View abstract
  4. Are Some Randomized Clinical Trials Impossible? J Pediatr Orthop. 2021 Jan; 41(1):e90-e93. View abstract
  5. Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children. Pediatr Blood Cancer. 2021 Apr; 68(4):e28833. View abstract
  6. Visual field outcomes in children treated for neurofibromatosis type 1-associated optic pathway gliomas: a multicenter retrospective study. J AAPOS. 2020 12; 24(6):349.e1-349.e5. View abstract
  7. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Neuro Oncol. 2020 10 14; 22(10):1527-1535. View abstract
  8. Neuro-Oncology Training for the Child Neurology Resident. J Child Neurol. 2021 Jan; 36(1):79-82. View abstract
  9. Novel predictive scoring system for morbid hypothalamic obesity in patients with pediatric craniopharyngioma. Childs Nerv Syst. 2021 Feb; 37(2):403-410. View abstract
  10. Assessment of provider perspectives on otoprotection research for children and adolescents: A Children's Oncology Group Cancer Control and Supportive Care Committee survey. Pediatr Blood Cancer. 2020 11; 67(11):e28647. View abstract
  11. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma. J Neurooncol. 2020 Sep; 149(2):253-262. View abstract
  12. Prescription Psychoactive Medication Use in Adolescent Survivors of Childhood Cancer and Association With Adult Functional Outcomes. JNCI Cancer Spectr. 2020 Oct; 4(5):pkaa057. View abstract
  13. Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study. Genet Med. 2020 11; 22(11):1794-1802. View abstract
  14. The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities. Oncologist. 2020 07; 25(7):e1109-e1116. View abstract
  15. Genomics of MPNST (GeM) Consortium: Rationale and Study Design for Multi-Omic Characterization of NF1-Associated and Sporadic MPNSTs. Genes (Basel). 2020 04 02; 11(4). View abstract
  16. Natural History and Management of Incidentally Discovered Focal Brain Lesions Indeterminate for Tumor in Children. Neurosurgery. 2020 03 01; 86(3):357-365. View abstract
  17. Visual spatial learning outcomes for clinical trials in neurofibromatosis type 1. Ann Clin Transl Neurol. 2020 02; 7(2):245-249. View abstract
  18. Optimizing Postoperative Surveillance of Pediatric Low-Grade Glioma Using Tumor Behavior Patterns. Neurosurgery. 2020 02 01; 86(2):288-297. View abstract
  19. Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1. J Atten Disord. 2019 Dec 14; 1087054719894384. View abstract
  20. Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1. Ann Clin Transl Neurol. 2019 12; 6(12):2555-2565. View abstract
  21. Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1. Hum Mutat. 2020 01; 41(1):299-315. View abstract
  22. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. J Clin Oncol. 2019 12 10; 37(35):3446-3454. View abstract
  23. The Impact of Intraoperative Electrocorticography on Seizure Outcome After Resection of Pediatric Brain Tumors: A Cohort Study. Neurosurgery. 2019 09 01; 85(3):375-383. View abstract
  24. Sixty years single institutional experience with pediatric craniopharyngioma: between the past and the future. Childs Nerv Syst. 2020 02; 36(2):291-296. View abstract
  25. Health Supervision for Children With Neurofibromatosis Type 1. Pediatrics. 2019 05; 143(5). View abstract
  26. From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis. Am J Med Genet A. 2019 06; 179(6):1098-1106. View abstract
  27. A Review of Chronic Leukoencephalopathy among Survivors of Childhood Cancer. Pediatr Neurol. 2019 12; 101:2-10. View abstract
  28. Correction: Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation. Genet Med. 2019 03; 21(3):764-765. View abstract
  29. Pain affect disrupted in children with posterior cerebellar tumor resection. Ann Clin Transl Neurol. 2019 02; 6(2):344-354. View abstract
  30. Risk factors for chemotherapy-induced nausea in pediatric patients receiving highly emetogenic chemotherapy. Pediatr Blood Cancer. 2019 04; 66(4):e27584. View abstract
  31. Identifying clinical practice guidelines for the supportive care of children with cancer: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2019 01; 66(1):e27471. View abstract
  32. Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation. Genet Med. 2019 04; 21(4):867-876. View abstract
  33. Peripheral neuropathy in children and adolescents treated for cancer. Lancet Child Adolesc Health. 2018 10; 2(10):744-754. View abstract
  34. The management of childhood cancer survivors at risk for stroke: A Delphi survey of regional experts. Pediatr Blood Cancer. 2018 12; 65(12):e27394. View abstract
  35. 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. . 2018 05; 176(5):1258-1269. View abstract
  36. The Effectiveness of a Hospital-Based School Liaison Program: A Comparative Study of Parental Perception of School Supports for Children With Pediatric Cancer and Neurofibromatosis Type 1. J Pediatr Oncol Nurs. 2018 Jul/Aug; 35(4):276-286. View abstract
  37. Children's at Home: Pilot Study Assessing Dedicated Social Media for Parents of Adolescents with Neurofibromatosis Type 1. J Genet Couns. 2018 04; 27(2):505-517. View abstract
  38. Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a Childhood Cancer Survivor Study report. Neuro Oncol. 2018 01 10; 20(1):132-142. View abstract
  39. Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848. Am J Hum Genet. 2018 01 04; 102(1):69-87. View abstract
  40. Acupressure bands do not improve chemotherapy-induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: A single-blinded, randomized controlled trial. Cancer. 2018 03 15; 124(6):1188-1196. View abstract
  41. School liaison program supporting children with neurofibromatosis type 1: a model of care for children with chronic disease. Genet Med. 2018 07; 20(7):785-788. View abstract
  42. Liver Failure as the Presentation of Ornithine Transcarbamylase Deficiency in a 13-Month-Old Female. JIMD Rep. 2018; 40:17-22. View abstract
  43. Visual and ocular motor outcomes in children with posterior fossa tumors. J AAPOS. 2017 Oct; 21(5):375-379. View abstract
  44. Brain tumors and epileptic spasms: Natural history and outcomes. Epilepsy Behav. 2017 10; 75:25-28. View abstract
  45. Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. J Neurooncol. 2017 Oct; 135(1):201-211. View abstract
  46. Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study. Neuro Oncol. 2017 05 01; 19(5):689-698. View abstract
  47. The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis. Am J Med Genet A. 2017 Jun; 173(6):1714-1721. View abstract
  48. A 15-Month-Old Girl Presenting With Clitoromegaly and a Chest Mass. Semin Pediatr Neurol. 2018 07; 26:128-131. View abstract
  49. A 15-Year-Old Girl With Sudden Onsent Reversible Neurologic Symptoms After Cranial Irradiation for Medulloblastoma. Semin Pediatr Neurol. 2018 07; 26:124-127. View abstract
  50. Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. Neuro Oncol. 2017 02 01; 19(2):289-297. View abstract
  51. Analysis of copy number variants in 11 pairs of monozygotic twins with neurofibromatosis type 1. . 2017 Mar; 173(3):647-653. View abstract
  52. Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Neurology. 2016 Dec 13; 87(24):2575-2584. View abstract
  53. Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention. Neurology. 2016 Aug 16; 87(7 Suppl 1):S21-30. View abstract
  54. Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome. Circulation. 2016 Jul 12; 134(2):114-25. View abstract
  55. Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1. J Neurooncol. 2016 08; 129(1):173-8. View abstract
  56. Vitamin B12 Deficiency Presenting with Neurological Dysfunction in an Adolescent. Pediatr Neurol. 2016 09; 62:66-70. View abstract
  57. Myxopapillary ependymomas in children: imaging, treatment and outcomes. J Neurooncol. 2016 Jan; 126(1):165-174. View abstract
  58. MITF is a critical regulator of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in malignant melanoma. Pigment Cell Melanoma Res. 2015 Nov; 28(6):736-40. View abstract
  59. CEACAM1-4L Promotes Anchorage-Independent Growth in Melanoma. Front Oncol. 2015; 5:234. View abstract
  60. Neurocutaneous Syndromes and Brain Tumors. J Child Neurol. 2016 10; 31(12):1399-411. View abstract
  61. Bacillus cereus Cerebral Abscess During Induction Chemotherapy for Childhood Acute Leukemia. J Pediatr Hematol Oncol. 2015 Oct; 37(7):568-9. View abstract
  62. Incidence, risk factors, and longitudinal outcome of seizures in long-term survivors of pediatric brain tumors. Epilepsia. 2015 Oct; 56(10):1599-604. View abstract
  63. Risk of seizures in children with tectal gliomas. Epilepsia. 2015 Sep; 56(9):e139-42. View abstract
  64. CEACAM1-3S Drives Melanoma Cells into NK Cell-Mediated Cytolysis and Enhances Patient Survival. Cancer Res. 2015 May 01; 75(9):1897-907. View abstract
  65. Hutchinson-Gilford progeria syndrome. Handb Clin Neurol. 2015; 132:249-64. View abstract
  66. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol. 2015 Apr; 17(4):596-603. View abstract
  67. Update from the 2013 International Neurofibromatosis Conference. . 2014 Dec; 164A(12):2969-78. View abstract
  68. Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors. J Natl Cancer Inst. 2014 Aug; 106(8). View abstract
  69. Recurrence after gross-total resection of low-grade pediatric brain tumors: the frequency and timing of postoperative imaging. J Neurosurg Pediatr. 2014 Oct; 14(4):356-64. View abstract
  70. Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma. Ann Neurol. 2014 May; 75(5):799-800. View abstract
  71. Cerebellar mutism after posterior fossa tumor resection: case discussion and recommendations for psychoeducational intervention. J Pediatr Oncol Nurs. 2014 Mar-Apr; 31(2):78-83. View abstract
  72. Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer. 2014 Jul; 61(7):1173-9. View abstract
  73. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. . 2014 Mar; 164A(3):563-78. View abstract
  74. Functional outcome measures for NF1-associated optic pathway glioma clinical trials. Neurology. 2013 Nov 19; 81(21 Suppl 1):S15-24. View abstract
  75. Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment. Neurology. 2013 Jul 30; 81(5):427-30. View abstract
  76. Predictors of neoplastic disease in children with isolated pituitary stalk thickening. Pediatr Blood Cancer. 2013 Oct; 60(10):1630-5. View abstract
  77. Calvarial defects and skeletal dysplasia in patients with neurofibromatosis Type 1. J Neurosurg Pediatr. 2013 Apr; 11(4):410-6. View abstract
  78. Moyamoya syndrome associated with neurofibromatosis Type 1: perioperative and long-term outcome after surgical revascularization. J Neurosurg Pediatr. 2013 Apr; 11(4):417-25. View abstract
  79. Children's Oncology Group's 2013 blueprint for research: cancer control and supportive care. Pediatr Blood Cancer. 2013 Jun; 60(6):1027-30. View abstract
  80. Prevalence and predictors of prescription psychoactive medication use in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Cancer Surviv. 2013 Mar; 7(1):104-14. View abstract
  81. Imaging characteristics of cerebrovascular arteriopathy and stroke in Hutchinson-Gilford progeria syndrome. AJNR Am J Neuroradiol. 2013 May; 34(5):1091-7. View abstract
  82. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A. 2012 Oct 09; 109(41):16666-71. View abstract
  83. Academic women faculty: are they finding the mentoring they need? J Womens Health (Larchmt). 2012 Nov; 21(11):1201-8. View abstract
  84. Morning glory disc anomaly in association with ipsilateral optic nerve glioma. Arch Ophthalmol. 2012 Aug; 130(8):1082-3. View abstract
  85. 168 Moyamoya Syndrome Associated with Neurofibromatosis Type 1 in Children. Neurosurgery. 2012 Aug 01; 71(2):E566. View abstract
  86. Psychoactive medication use and neurocognitive function in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor study. Pediatr Blood Cancer. 2013 Mar; 60(3):486-93. View abstract
  87. Sleep dysfunction in long term survivors of craniopharyngioma. J Neurooncol. 2012 Jul; 108(3):543-9. View abstract
  88. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol. 2012 Jun; 14(6):790-7. View abstract
  89. Craniofacial abnormalities in Hutchinson-Gilford progeria syndrome. AJNR Am J Neuroradiol. 2012 Sep; 33(8):1512-8. View abstract
  90. [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation. J Neurooncol. 2012 Jul; 108(3):469-75. View abstract
  91. Introduction. Neurologic sequelae of cancer in children. Semin Pediatr Neurol. 2012 Mar; 19(1):1-2. View abstract
  92. Neurocognitive dysfunction in survivors of childhood brain tumors. Semin Pediatr Neurol. 2012 Mar; 19(1):35-42. View abstract
  93. Discovery of asymptomatic moyamoya arteriopathy in pediatric syndromic populations: radiographic and clinical progression. Neurosurg Focus. 2011 Dec; 31(6):E6. View abstract
  94. Neuro-oncology training for the child neurology resident. Semin Pediatr Neurol. 2011 Jun; 18(2):120-2. View abstract
  95. Long-term clinical outcomes following treatment of childhood craniopharyngioma. Pediatr Blood Cancer. 2011 Jul 01; 56(7):1120-6. View abstract
  96. Association of rapidly progressive moyamoya syndrome with bevacizumab treatment for glioblastoma in a child with neurofibromatosis type 1. J Child Neurol. 2011 Feb; 26(2):228-30. View abstract
  97. Germinoma with malignant transformation to nongerminomatous germ cell tumor. J Neurosurg Pediatr. 2010 Sep; 6(3):295-8. View abstract
  98. Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. Pediatr Blood Cancer. 2010 Jul 01; 54(7):890-6. View abstract
  99. Pilot study of a novel computerized task to assess spatial learning in children and adolescents with neurofibromatosis type 1. J Child Neurol. 2010 Oct; 25(10):1195-202. View abstract
  100. Neurologic sequelae of brain tumors in children. J Child Neurol. 2009 Nov; 24(11):1446-54. View abstract
  101. Algal lipid bodies: stress induction, purification, and biochemical characterization in wild-type and starchless Chlamydomonas reinhardtii. Eukaryot Cell. 2009 Dec; 8(12):1856-68. View abstract
  102. Medical, psychological, cognitive and educational late-effects in pediatric low-grade glioma survivors treated with surgery only. Pediatr Blood Cancer. 2009 Sep; 53(3):417-23. View abstract
  103. A prospective, blinded analysis of A-PROTEIN (recoverin or CAR protein) levels in pediatric patients with central nervous system tumors. Pediatr Blood Cancer. 2009 Sep; 53(3):343-7. View abstract
  104. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol. 2009 Jan 20; 27(3):385-9. View abstract
  105. CNS relapse of acute myelogenous leukemia masquerading as pseudotumor cerebri. Pediatr Neurol. 2008 Nov; 39(5):355-7. View abstract
  106. Outcome of pediatric pineoblastoma after surgery, radiation and chemotherapy. J Neurooncol. 2008 Aug; 89(1):89-95. View abstract
  107. Gender differences in research grant applications and funding outcomes for medical school faculty. J Womens Health (Larchmt). 2008 Mar; 17(2):207-14. View abstract
  108. "The choking game": self-induced hypoxia presenting as recurrent seizurelike events. Epilepsy Behav. 2008 Apr; 12(3):486-8. View abstract
  109. Inherited disorders as a risk factor and predictor of neurodevelopmental outcome in pediatric cancer. Dev Disabil Res Rev. 2008; 14(3):229-37. View abstract
  110. Brainstem lesions in neurofibromatosis type 1. Neurosurgery. 2007 Oct; 61(4):762-6; discussion 766-7. View abstract
  111. Moyamoya following cranial irradiation for primary brain tumors in children. Neurology. 2007 Mar 20; 68(12):932-8. View abstract
  112. Extracranial metastases of glioblastoma in a child: case report and review of the literature. J Pediatr Hematol Oncol. 2007 Mar; 29(3):190-4. View abstract
  113. Molecular genetics of pediatric central nervous system tumors. Curr Oncol Rep. 2006 Nov; 8(6):423-9. View abstract
  114. Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. J Neurooncol. 2007 Mar; 82(1):95-101. View abstract
  115. Transverse myelitis after therapy for primitive neuroectodermal tumors. Pediatr Neurol. 2006 Aug; 35(2):122-5. View abstract
  116. Craniopharyngioma therapy: long-term effects on hypothalamic function. Neurologist. 2005 Jan; 11(1):55-60. View abstract
  117. Electroencephalographic correlate of juvenile Huntington's disease. J Child Neurol. 2004 Jul; 19(7):541-3. View abstract
  118. Research during pediatric residency: predictors and resident-determined influences. Acad Med. 2003 Dec; 78(12):1253-8. View abstract
  119. Pediatric brain tumors. Neurol Clin. 2003 Nov; 21(4):897-913. View abstract
  120. Transient global amnesia in a young adult with cyanotic heart disease. Pediatr Neurol. 2003 Oct; 29(4):334-6. View abstract
  121. Expression of voltage-activated chloride currents in acute slices of human gliomas. Neuroscience. 1998 Apr; 83(4):1161-73. View abstract
  122. Cell cycle-dependent expression of a glioma-specific chloride current: proposed link to cytoskeletal changes. Am J Physiol. 1997 10; 273(4):C1290-7. View abstract
  123. Biophysical and pharmacological characterization of chloride currents in human astrocytoma cells. Am J Physiol. 1996 May; 270(5 Pt 1):C1511-21. View abstract
  124. Human astrocytoma cells express a unique chloride current. Neuroreport. 1996 Apr 10; 7(5):1020-4. View abstract
  125. Human astrocytoma cells express a unique chloride current. Neuroreport. 1995 Dec 29; 7(1):343-7. View abstract
  126. Astrocyte Na+ channels are required for maintenance of Na+/K(+)-ATPase activity. J Neurosci. 1994 May; 14(5 Pt 1):2464-75. View abstract